[
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Declares US$1.64 Quarterly Dividend for Shareholders",
    "summary": "AbbVie (ABBV) recently affirmed a quarterly dividend of $1.64 per share, adding stability for shareholders amid a 12% quarterly price gain. Despite some company challenges, such as lower net income in Q2, the strong dividend outlook, positive trial results, and an increased revenue projection added momentum to AbbVie's stock performance. Additionally, the U.S. labor market's struggles have fueled expectations for Federal Reserve rate cuts, pushing Treasury yields lower. These market dynamics...",
    "url": "https://finnhub.io/api/news?id=d300191d2697e0529143e970813793eeddc58d356babe9c0e52d929ee5f6268f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757182625,
      "headline": "AbbVie (ABBV) Declares US$1.64 Quarterly Dividend for Shareholders",
      "id": 136669127,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) recently affirmed a quarterly dividend of $1.64 per share, adding stability for shareholders amid a 12% quarterly price gain. Despite some company challenges, such as lower net income in Q2, the strong dividend outlook, positive trial results, and an increased revenue projection added momentum to AbbVie's stock performance. Additionally, the U.S. labor market's struggles have fueled expectations for Federal Reserve rate cuts, pushing Treasury yields lower. These market dynamics...",
      "url": "https://finnhub.io/api/news?id=d300191d2697e0529143e970813793eeddc58d356babe9c0e52d929ee5f6268f"
    }
  },
  {
    "ts": null,
    "headline": "3 Stocks to Buy and Hold Forever",
    "summary": "These stocks are built for the long run.",
    "url": "https://finnhub.io/api/news?id=9148ab03f956c8134a21ef2acdd1cd20333648c384cdbdc26d29f34b35ecf700",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757158920,
      "headline": "3 Stocks to Buy and Hold Forever",
      "id": 136669087,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "These stocks are built for the long run.",
      "url": "https://finnhub.io/api/news?id=9148ab03f956c8134a21ef2acdd1cd20333648c384cdbdc26d29f34b35ecf700"
    }
  },
  {
    "ts": null,
    "headline": "Regenxbio: Remains A \"Buy Rating\" Despite BLA Review Delay Of RGX-121 For Hunter Syndrome",
    "summary": "Regenxbio's RGX-121 for Hunter syndrome saw its FDA review delayed to February 8, 2026, but strong 12-month surrogate endpoint data supports its potential...",
    "url": "https://finnhub.io/api/news?id=afda15be03372e01c74a49b590d1526f1ecce51b7bd665a618ca1e65f42d2f4c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757147390,
      "headline": "Regenxbio: Remains A \"Buy Rating\" Despite BLA Review Delay Of RGX-121 For Hunter Syndrome",
      "id": 136656032,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2228260742/image_2228260742.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Regenxbio's RGX-121 for Hunter syndrome saw its FDA review delayed to February 8, 2026, but strong 12-month surrogate endpoint data supports its potential...",
      "url": "https://finnhub.io/api/news?id=afda15be03372e01c74a49b590d1526f1ecce51b7bd665a618ca1e65f42d2f4c"
    }
  }
]